TDC
TEVA icon

Thompson Davis & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Thompson Davis & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
10,900
+500
+5% +$16.7K 0.22% 88
2026
Q1 		$313K Hold
10,400
– – 0.21% 80
2025
Q4 		$325K Hold
10,400
– – 0.19% 91
2025
Q3 		$210K Buy
+10,400
New +$183K 0.13% 119
2017
Q1 		– Sell
-271
Closed -$10K – 1230
2016
Q4 		$10K Hold
271
– – 0.02% 707
2016
Q3 		$12K Hold
271
– – 0.02% 626
2016
Q2 		$14K Hold
271
– – 0.02% 564
2016
Q1 		$15K Buy
271
+34
+14% +$2K 0.02% 542
2015
Q4 		$16K Sell
237
-112
-32% -$6.92K 0.02% 532
2015
Q3 		$20K Buy
349
+47
+16% +$3.05K 0.03% 469
2015
Q2 		$18K Hold
302
– – 0.02% 575
2015
Q1 		$19K Sell
302
-121
-29% -$7.04K 0.02% 545
2014
Q4 		$24K Buy
423
+61
+17% +$3.4K 0.03% 466
2014
Q3 		$19K Buy
+362
New +$19.2K 0.02% 483

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Thompson Davis & Co's TEVA Position: Q2 2026 in Review

Thompson Davis & Co increased its Teva Pharmaceuticals (TEVA) stake by 4.8% in Q2 2026, buying an estimated $16.7K and bringing the position to 10,900 shares worth $369K. The position accounts for 0.22% of the portfolio, ranked #88.

Thompson Davis & Co first reported a position in TEVA in Q3 2014 and has held it in 14 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Thompson Davis & Co held 10,900 shares of Teva Pharmaceuticals worth $369K as of Q2 2026.
  • Thompson Davis & Co bought 500 Teva Pharmaceuticals shares in Q2 2026, an estimated $16.7K.
  • Teva Pharmaceuticals made up 0.22% of Thompson Davis & Co's portfolio in Q2 2026, its #88 holding.
  • Thompson Davis & Co first reported a position in Teva Pharmaceuticals in Q3 2014 and has held it in 14 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Thompson Davis & Co's 13F filing for Q2 2026, filed 29 Jul 2026.